Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Li Liu 2 Articles
Metabolic Risk/Epidemiology
Article image
Healthy Lifestyle and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Large Prospective Cohort Study
Qing Chang, Yixiao Zhang, Tingjing Zhang, Zuyun Liu, Limin Cao, Qing Zhang, Li Liu, Shaomei Sun, Xing Wang, Ming Zhou, Qiyu Jia, Kun Song, Yang Ding, Yuhong Zhao, Kaijun Niu, Yang Xia
Diabetes Metab J. 2024;48(5):971-982.   Published online March 19, 2024
DOI: https://doi.org/10.4093/dmj.2023.0133
  • 2,358 View
  • 189 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The incidence density of metabolic dysfunction-associated fatty liver disease (MAFLD) and the effect of a healthy lifestyle on the risk of MAFLD remain unknown. We evaluated the prevalence and incidence density of MAFLD and investigated the association between healthy lifestyle and the risk of MAFLD.
Methods
A cross-sectional analysis was conducted on 37,422 participants to explore the prevalence of MAFLD. A cohort analysis of 18,964 individuals was conducted to identify the incidence of MAFLD, as well as the association between healthy lifestyle and MAFLD. Cox proportional hazards regression was used to calculate the hazard ratio (HR) and 95% confidence interval (CI) with adjustments for confounding factors.
Results
The prevalence of MAFLD, non-alcoholic fatty liver disease, and their comorbidities were 30.38%, 28.09%, and 26.13%, respectively. After approximately 70 thousand person-years of follow-up, the incidence densities of the three conditions were 61.03, 55.49, and 51.64 per 1,000 person-years, respectively. Adherence to an overall healthy lifestyle was associated with a 19% decreased risk of MAFLD (HR, 0.81; 95% CI, 0.72 to 0.92), and the effects were modified by baseline age, sex, and body mass index (BMI). Subgroup analyses revealed that younger participants, men, and those with a lower BMI experienced more significant beneficial effects from healthy lifestyle.
Conclusion
Our results highlight the beneficial effect of adherence to a healthy lifestyle on the prevention of MAFLD. Health management for improving dietary intake, physical activity, and smoking and drinking habits are critical to improving MAFLD.

Citations

Citations to this article as recorded by  
  • Diagnostic indicators and lifestyle interventions of metabolic-associated fatty liver disease
    Tianzhu Chen, Xiang Qin, Jianping Jiang, Beihui He
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • Sex differences in pathogenesis and treatment of dyslipidemia in patients with type 2 diabetes and steatotic liver disease
    Tatjana Ábel, Béla Benczúr, Éva Csajbókné Csobod
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Associations of traditional healthy lifestyle and sleep quality with metabolic dysfunction-associated fatty liver disease: two population-based studies
    Jialu Yang, Qi Zhang, Wanying Zhao, Bingqi Ye, Siqi Li, Zhuoyu Zhang, Jingmeng Ju, Jialin He, Min Xia, Tiantian Xiong, Yan Liu
    Nutrition & Diabetes.2024;[Epub]     CrossRef
Basic Research
Article image
Sulforaphane Ameliorates Diabetes-Induced Renal Fibrosis through Epigenetic Up-Regulation of BMP-7
Lili Kong, Hongyue Wang, Chenhao Li, Huiyan Cheng, Yan Cui, Li Liu, Ying Zhao
Diabetes Metab J. 2021;45(6):909-920.   Published online June 4, 2021
DOI: https://doi.org/10.4093/dmj.2020.0168
  • 6,579 View
  • 152 Download
  • 22 Web of Science
  • 23 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFPubReader   ePub   
Background
The dietary agent sulforaphane (SFN) has been reported to reduce diabetes-induced renal fibrosis, as well as inhibit histone deacetylase (HDAC) activity. Bone morphologic protein 7 (BMP-7) has been shown to reduce renal fibrosis induced by transforming growth factor-beta1. The aim of this study was to investigate the epigenetic effect of SFN on BMP-7 expression in diabetes-induced renal fibrosis.
Methods
Streptozotocin (STZ)-induced diabetic mice and age-matched controls were subcutaneously injected with SFN or vehicle for 4 months to measure the in vivo effects of SFN on the kidneys. The human renal proximal tubular (HK11) cell line was used to mimic diabetic conditions in vitro. HK11 cells were transfected to over-express HDAC2 and treated with high glucose/palmitate (HG/Pal) to explore the epigenetic modulation of BMP-7 in SFN-mediated protection against HG/Pal-induced renal fibrosis.
Results
SFN significantly attenuated diabetes-induced renal fibrosis in vivo. Among all of the HDACs we detected, HDAC2 activity was markedly elevated in the STZ-induced diabetic kidneys and HG/Pal-treated HK11 cells. SFN inhibited the diabetes-induced increase in HDAC2 activity which was associated with histone acetylation and transcriptional activation of the BMP-7 promoter. HDAC2 over-expression reduced BMP-7 expression and abolished the SFN-mediated protection against HG/Pal-induced fibrosis in vitro.
Conclusion
Our study demonstrates that the HDAC inhibitor SFN protects against diabetes-induced renal fibrosis through epigenetic up-regulation of BMP-7.

Citations

Citations to this article as recorded by  
  • Underlying mechanisms and molecular targets of genistein in the management of type 2 diabetes mellitus and related complications
    Tao Jiang, Yuhe Dong, Wanying Zhu, Tong Wu, Linyan Chen, Yuantong Cao, Xi Yu, Ye Peng, Ling Wang, Ying Xiao, Tian Zhong
    Critical Reviews in Food Science and Nutrition.2024; 64(31): 11543.     CrossRef
  • Sulforaphane reduces adipose tissue fibrosis via promoting M2 macrophages polarization in HFD fed-mice
    Zhenzhen Zhang, Huali Chen, Cheng Pan, Rui Li, Wangsheng Zhao, Tianzeng Song
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2024; 1871(2): 119626.     CrossRef
  • Potential of Plant-Derived Compounds in Preventing and Reversing Organ Fibrosis and the Underlying Mechanisms
    Patrícia dos Santos Azeredo, Daping Fan, E. Angela Murphy, Wayne E. Carver
    Cells.2024; 13(5): 421.     CrossRef
  • Pulmonary hypertension and chronic kidney disease: prevalence, pathophysiology and outcomes
    Katarina Zeder, Edward D. Siew, Gabor Kovacs, Evan L. Brittain, Bradley A. Maron
    Nature Reviews Nephrology.2024; 20(11): 742.     CrossRef
  • Role of Histone Modifications in Kidney Fibrosis
    Shengyu Pan, Tianhui Yuan, Yuqi Xia, Weimin Yu, Xiangjun Zhou, Fan Cheng
    Medicina.2024; 60(6): 888.     CrossRef
  • Unveiling the Nutritional Veil of Sulforaphane: With a Major Focus on Glucose Homeostasis Modulation
    Yanan Wang, Xiaoyun He, Nan Cheng, Kunlun Huang
    Nutrients.2024; 16(12): 1877.     CrossRef
  • Nonsurgical therapy for lumbar spinal stenosis caused by ligamentum flavum hypertrophy: A review
    Nan Fang, Zhigang Wang, Jiecheng Jiang, Aofei Yang, Tian Mao, Zitong Wang, Qian Chen
    Medicine.2024; 103(27): e38782.     CrossRef
  • Beneficial role of broccoli and its active ingredient, sulforaphane in the treatment of diabetes
    Aminu Mohammed, Hafsat Abdullahi Mohammed
    Phytomedicine Plus.2023; 3(2): 100431.     CrossRef
  • The Role of Histone Modifications in the Pathogenesis of Diabetic Kidney Disease
    Christodoula Kourtidou, Konstantinos Tziomalos
    International Journal of Molecular Sciences.2023; 24(6): 6007.     CrossRef
  • Insights into the Molecular Mechanisms of NRF2 in Kidney Injury and Diseases
    Da-Wei Lin, Yung-Chien Hsu, Cheng-Chih Chang, Ching-Chuan Hsieh, Chun-Liang Lin
    International Journal of Molecular Sciences.2023; 24(7): 6053.     CrossRef
  • Beneficial Effects of Sulforaphane on Diabetes and Its Complications via Both Nrf2-Dependent and Independent Mechanisms
    Minhyuk Kim, Joo Young Lee
    Food Supplements and Biomaterials for Health.2023;[Epub]     CrossRef
  • Sulforaphane exhibits potent renoprotective effects in preclinical models of kidney diseases: A systematic review and meta-analysis
    Elisa B. Monteiro, Matheus Ajackson, Milena B. Stockler-Pinto, Fitsum Guebre-Egziabher, Julio B. Daleprane, Christophe O. Soulage
    Life Sciences.2023; 322: 121664.     CrossRef
  • Integrated single-cell RNA-seq analysis revealed podocyte injury through activation of the BMP7/AMPK/mTOR mediated autophagy pathway
    Hongzhou Lin, Huihui Chen, Rengcheng Qian, Guoqi Tang, Yinjuan Ding, Yalan Jiang, Congde Chen, Dexuan Wang, Maoping Chu, Xiaoling Guo
    Chemico-Biological Interactions.2023; 382: 110559.     CrossRef
  • Sulforaphane: A nutraceutical against diabetes-related complications
    Sinenhlanhla X.H. Mthembu, Sithandiwe E. Mazibuko-Mbeje, Marakiya T. Moetlediwa, Ndivhuwo Muvhulawa, Sonia Silvestri, Patrick Orlando, Bongani B. Nkambule, Christo J.F. Muller, Duduzile Ndwandwe, Albertus K. Basson, Luca Tiano, Phiwayinkosi V. Dludla
    Pharmacological Research.2023; 196: 106918.     CrossRef
  • Nrf2/HO-1 as a therapeutic target in renal fibrosis
    Emad H.M. Hassanein, Islam M. Ibrahim, Esraa K. Abd-alhameed, Zeina W. Sharawi, Fatima A. Jaber, Hanan S. Althagafy
    Life Sciences.2023; 334: 122209.     CrossRef
  • A mechanistic overview of sulforaphane and its derivatives application in diabetes and its complications
    Neda Mohamadi, Vafa Baradaran Rahimi, Mohammad Reza Fadaei, Fatemeh Sharifi, Vahid Reza Askari
    Inflammopharmacology.2023; 31(6): 2885.     CrossRef
  • The HDAC2/SP1/miR-205 feedback loop contributes to tubular epithelial cell extracellular matrix production in diabetic kidney disease
    Zongji Zheng, Shuting Zhang, Jiaqi Chen, Meina Zou, Yanlin Yang, Wen Lu, Shijing Ren, Xiangyu Wang, Wenhui Dong, Zikun Zhang, Ling Wang, Meiping Guan, Gladys L.Y. Cheing, Yaoming Xue, Yijie Jia
    Clinical Science.2022; 136(3): 223.     CrossRef
  • BMP-7 Upregulates Id2 Through the MAPK Signaling Pathway to Improve Diabetic Tubulointerstitial Fibrosis and the Intervention of Oxymatrine
    Yawen Xiao, Dan Liang, Zhiyang Li, Zhaowei Feng, Zhiping Yuan, Fan Zhang, Yuanyuan Wang, Yuxia Zhou, Mingjun Shi, Lingling Liu, Ying Xiao, Bing Guo
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • HDAC1 Promotes Myocardial Fibrosis in Diabetic Cardiomyopathy by Inhibiting BMP-7 Transcription Through Histone Deacetylation
    Chun Ouyang, Lei Huang, Xiaoqiang Ye, Mingming Ren, Zhen Han
    Experimental and Clinical Endocrinology & Diabetes.2022; 130(10): 660.     CrossRef
  • Class IIa histone deacetylase inhibition ameliorates acute kidney injury by suppressing renal tubular cell apoptosis and enhancing autophagy and proliferation
    Jialu Li, Chao Yu, Fengchen Shen, Binbin Cui, Na Liu, Shougang Zhuang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression
    Jiayu Wang, Jiaxing Li, Xin Zhang, Min Zhang, Xiaopeng Hu, Hang Yin
    Frontiers in Molecular Biosciences.2022;[Epub]     CrossRef
  • The improvement of sulforaphane in type 2 diabetes mellitus (T2DM) and related complications: A review
    Mengjiao Wang, Min Chen, Rui Guo, Yangyang Ding, Haihui Zhang, Yuanqing He
    Trends in Food Science & Technology.2022; 129: 397.     CrossRef
  • Defining therapeutic targets for renal fibrosis: Exploiting the biology of pathogenesis
    Hao Yan, Jiangxin Xu, Zhifei Xu, Bo Yang, Peihua Luo, Qiaojun He
    Biomedicine & Pharmacotherapy.2021; 143: 112115.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP